Developed by leading cannabinoid research and development company Axim Biotech, the cannabidiol (CBD) gum is designed to alleviate symptoms of IBS.
Cannabinoid-containing chewing gum, CanChew Plus, has entered a clinical trial to evaluate its efficacy in the treatment of irritable bowel syndrome (IBS). Developed by leading cannabinoid research and development company Axim Biotech, the cannabidiol (CBD) gum is designed to alleviate symptoms of IBS.
The clinical studies will be conducted at the Wageningen University in the Netherlands, and will include 40 patients aged 18-65, diagnosed with IBS according to ROME 3 criteria. Although IBS is the most common functional gastrointestinal disorder, its physical symptoms are often painful and difficult to manage. The CanChew Plus trial is the first of its kind to evaluate IBS treatment through CBD chewing gum.
The trials will assess pain reduction in patients with IBS using cannabinoid-containing gum, and general relief and change in stool frequency will also be recorded. Functional, controlled-release CBD chewing gum and matching placebo gums will be tested in participants for the clinical studies. Trial protocol allows patients to use up to 6 chewing gums a day to manage stomach cramps, bloating, pain, and other IBS related symptoms.
AXIM Biotech Enters IBS Clinical Trial for CanChew CBD Chewing Gum [news release]. New York. https://globenewswire.com/news-release/2017/01/18/906670/0/en/AXIM-Biotech-Enters-IBS-Clinical-Trial-for-CanChew-CBD-Chewing-Gum.html. Accessed Jan. 18, 2017.